SCHEMBL12408098

SCHEMBL12408098

[C-]#[N+]c1cn(COCC[Si](C)(C)C)c(C(=O)Nc2ccc(C3CNC(=NSOOC)NC3)cc2C2=CCCCC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 16/20 0.39
▸ KIT P10721 8/20 0.38
▸ NTRK1 P04629 4/20 0.36
▸ LCK P06239 4/20 0.36
▸ AXL P30530 4/20 0.36
▸ FLT3 P36888 4/20 0.36
▸ CYP3A4 P08684 3/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ BMPR1B O00238 2/20 0.35
▸ PLK4 O00444 2/20 0.35
▸ STK25 O00506 2/20 0.35
▸ RIOK3 O14730 2/20 0.35
▸ CHEK1 O14757 2/20 0.35
▸ GAK O14976 2/20 0.35
▸ DCLK1 O15075 2/20 0.35
▸ MUSK O15146 2/20 0.35
▸ EPHB6 O15197 2/20 0.35
▸ PDPK1 O15530 2/20 0.35
▸ MAP3K13 O43283 2/20 0.35
▸ DAPK3 O43293 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12408097 0.90 CSF1R (0.41) CSF1RKITNTRK1LCKAXL
SCHEMBL13096528 0.81 CSF1R (0.54) CSF1RKITNTRK1LCKAXL
SCHEMBL12408099 0.81 CSF1R (0.47) CSF1RKITNTRK1LCKAXL
SCHEMBL13096494 0.80 KIT (0.45) CSF1RKITNTRK1LCKAXL
SCHEMBL1858489 0.79 KIT (0.50) CSF1RKITNTRK1LCKAXL
SCHEMBL12489618 0.79 KIT (0.50) CSF1RKITNTRK1LCKAXL
SCHEMBL1865625 0.78 CSF1R (0.57) CSF1RKITNTRK1LCKAXL
SCHEMBL1859596 0.78 KIT (0.48) CSF1RKITNTRK1LCKAXL
SCHEMBL12408029 0.77 CSF1R (0.44) CSF1RKITNTRK1LCKAXL
SCHEMBL1856316 0.76 CSF1R (0.57) CSF1RKITNTRK1LCKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 — — US disclosed
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent ILLIG CARL R 2008-11-06 — — US disclosed
US-7414050-B2 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2008-08-19 — — US disclosed
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, PNCK CSF1R 249/4885KIT 119/4885NTRK1 134/4885
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, CAMK4 CSF1R 249/4885KIT 214/4885NTRK1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback